Monday Mar 28, 2022

Non-Small Cell Lung Cancer (NSCLC) with Dr. Thomas Stinchcombe

On this episode we hear from Thoracic Medical oncologist Dr. Thomas Stinchcombe. Dr. Stinchcombe is a member of Duke Cancer Institute, and Thoracic Oncology Program at Duke University in Durham, North Carolina.

Dr. Stinchcombe explains whether or not they would recommend RET inhibitors as first line therapy for a RET-fusion positive metastatic Non-Small Cell Lung Cancer patient, what drugs are available to treat patients with Non-Small Lung Cancer and MET exon 14 skipping alterations, the significance of a metastatic Non-Small Cell Lung Cancer patient with a ERBB2 or HER2 alteration & whether there are specific mutations that are targetable for HER2. We conclude with a breakdown of the role of immune check point inhibitors in patients with resected Non-Small Cell Lung Cancer & the role of adjuvant therapy with atezolizumab.

Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos.

New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

2022 All rights reserved.

Version: 20230822